| 王墨培,李惠平,张照辉,等.89SrCl2在治疗乳腺癌骨转移中的临床疗效[J].中华放射医学与防护杂志,2008,28(3):264-266.WANG Mo-pei,LI Hui-ping,ZHANG Zhao-hui,et al.Clinical effect of 89SrCl2 in the treatment of breast cancer patients with bone metastasis[J].Chin J Radiol Med Prot,2008,28(3):264-266 |
| 89SrCl2在治疗乳腺癌骨转移中的临床疗效 |
| Clinical effect of 89SrCl2 in the treatment of breast cancer patients with bone metastasis |
| 投稿时间：2008-01-31 |
| DOI： |
| 中文关键词: 89SrCl2 乳腺癌 骨转移 血液学毒性 |
| 英文关键词:89SrCl2 Breastcancer Bonemetastasis Hematological toxicity |
| 基金项目: |
|
| 摘要点击次数: 3303 |
| 全文下载次数: 1889 |
| 中文摘要: |
| 目的 评价89SrCl2治疗乳腺癌骨转移的临床疗效,及其血液学毒副作用。方法 51例患者接受89SrCl2治疗,静脉注射剂量为2.22 MBq/kg体重,观察治疗前后止痛效果,病灶变化和外周血细胞变化。结果 患者疼痛完全缓解率为37.7%(17/45),总缓解率为84.4%。病灶治疗有效率为62.7%(32/51)。治疗后1个月白细胞和血小板减少者分别为76.5%和62.7%。3个月后大多数患者经治疗血象恢复到正常。结论 89SrCl2可安全、有效地治疗乳腺癌骨转移患者的疼痛,并对其生活质量有所改善。 |
| 英文摘要: |
| Objective To evaluate the clinical effect of 89SrCl2 as a palliative therapy for breast cancer patients with bone metastasis, and to observe the hematological toxicity induced by 89SrCl2 treatment. Methods 89SrCl2 dosage was 2.22 MBq/kg each time by intravenous for 51 patients. The analog scale, the cancer size and the hematological toxicity of 89SrCl2 treatment were observed. Results 17 patients (37.7%) among 45 patients became free of pain. The total pain relief rate was 84.4%.The response rate of metastatic sites was 62.7%. Approximately 76.5% of patients experienced neutropenia one month after theatment,whereas 62.7% of patients experienced thrombocytopenia. But the most of the patients could recover to the normal level 3 months after treatment. Conclusions 89SrCl2 is an effective and safe way for the pain relief and the life quality improvement in breast cancer patients with bone metastasis. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|